Adocia (ADOC) Investor Presentation summary
Event summary combining transcript, slides, and related documents.
Investor Presentation summary
27 Jun, 2025Leadership and team
Management team renewed, led by CEO Olivier Soula and CFO/COO Mathieu-William Gilbert, with backgrounds at Avadel, Novo Nordisk, KPMG, and Sanofi.
Team of 80 experts, including 35 PhDs/MDs/PharmDs, based in Lyon, France.
Market focus and challenges
Focus on diabetes and obesity, addressing chronic pandemics caused by peptide dysregulation.
Targets mass populations and aims to improve treatment adherence through innovative peptide delivery.
Technology platforms and pipeline
Four proprietary platforms: BioChaperone®, AdOral®, AdoGel™, and AdoShell® for peptide delivery.
Pipeline includes clinical and preclinical assets for diabetes, obesity, and cell therapy, with several in partnership or negotiation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Adocia
- Strong cash position and positive R&D progress support strategic focus on BioChaperone®.ADOC
Q2 2026 TU - Innovative peptide platforms drive growth in diabetes and obesity therapeutics.ADOCInvestor presentation
- BC Lispro/BCLIS achieved superior postprandial and daily glucose control with non-inferior HbA1c.ADOCStudy result
- Cash runway secured to Q2 2027; BioChaperone® prioritized after positive study results.ADOCQ1 2026 TU
- Pipeline advances and new financing extend cash runway to Q2 2027 despite wider net loss.ADOCH2 2025
- Strong clinical progress, robust cash, and leadership changes mark a transformative quarter.ADOCQ4 2025 TU
- Strong cash position, positive Phase 3 results, and advancing R&D drive future growth.ADOCQ3 2025 TU
- Net loss of €9.3M in H1 2025, cash runway extended to Q2 2026 after capital raise and milestone.ADOCH1 2025
- Cash position strengthened and pipeline progress set stage for key milestones in 2025.ADOCH1 2025 TU